Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1Phase 1 1

Status

Completed 3Not yet recruiting 2Unknown 1

Sponsor Class

INDUSTRY 4OTHER_GOV 1OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 105Gastrointestinal 56Breast 27Sarcoma 21Gynecologic 19Head & Neck 18CNS 11Endocrine 8Other solid neoplasm 7Tumor-Agnostic 6Genitourinary 5NET 2Dermatologic 2

Conditions

Neoplasms 4Neoplasm Metastasis 2

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Radiotherapy 47Capecitabine 47Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
anlotinib × Tumor-Agnostic × Clear all
NCT07562581 2026-05-01

A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 2 Not yet recruiting
48 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT06456138 2024-06-13

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

Shanghai Chest Hospital

Phase 1/2 Not yet recruiting
60 enrolled
Tumor-Agnostic

Neoplasms

NCT04055792 2023-06-28

Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC

Henan Cancer Hospital

Phase 2 Completed
42 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01878448 2019-05-22

ALTN/STS

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
166 enrolled
Tumor-Agnostic

Neoplasms

NCT01874873 2019-05-21

ALTN/MTC

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
58 enrolled
Tumor-Agnostic

Neoplasms

NCT02752516 2017-09-18

A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Unknown
16 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡